VAL-1221

DRUG2 trials

Sponsors

Valerion Therapeutics, LLC, Parasail, LLC

Conditions

Lafora DiseasePompe Disease

Phase 1

VAL-1221 Delivered Intravenously in Ambulatory and Ventilator-free Participants With Late-Onset Pompe Disease

TerminatedNCT02898753

Valerion Therapeutics, LLCPompe Disease

Start: 2017-06-21End: 2020-03-25Updated: 2020-06-02

Unknown Phase

Intravenous VAL-1221 Lafora Expanded Access Protocol

Parasail, LLCLafora Disease

Updated: 2023-07-05

Related Papers

VAL-1221 for the treatment of patients with Lafora disease: study protocol for a single-arm, open-label clinical trial

BMJ Open2024-10-018 citations